EDSA
Price
$2.77
Change
-$0.08 (-2.81%)
Updated
Oct 22, 04:56 PM (EDT)
Capitalization
27.48M
50 days until earnings call
Intraday BUY SELL Signals
ORMP
Price
$4.11
Change
-$0.03 (-0.72%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
172.21M
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDSA vs ORMP

EDSA vs ORMP Comparison Chart in %
View a ticker or compare two or three
VS
EDSA vs. ORMP commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDSA is a Hold and ORMP is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EDSA with price predictions
Oct 21, 2026

EDSA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 12, 2026

EDSA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 41 cases where EDSA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EDSA's RSI Indicator exited the oversold zone, 38 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDSA advanced for three days, in 176 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDSA as a result. In 86 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for EDSA turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 40 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

The 50-day moving average for EDSA moved below the 200-day moving average on September 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for EDSA entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. EDSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: EDSA's P/B Ratio (68.869) is slightly higher than the industry average of (2.988). P/E Ratio (-1.657) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for ORMP with price predictions
Oct 21, 2026

ORMP's Indicator enters downward trend

The Aroon Indicator for ORMP entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator formed such a pattern. In 156 of the 186 cases the stock moved lower. This puts the odds of a downward move at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 65 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

ORMP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ORMP crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Oscillator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORMP advanced for three days, in 216 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.542) is normal, around the industry mean (2.988). P/E Ratio (0.976) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.242) settles around the average of (123.903) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
EDSA vs ORMP: Fundamental Ratings
EDSA
ORMP
OUTLOOK RATING
1..100
7861
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10015
PRICE GROWTH RATING
1..100
6543
P/E GROWTH RATING
1..100
992
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (66) in the Pharmaceuticals Other industry is somewhat better than the same rating for EDSA (100) in the null industry. This means that ORMP’s stock grew somewhat faster than EDSA’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EDSA (100) in the null industry. This means that ORMP’s stock grew similarly to EDSA’s over the last 12 months.

ORMP's SMR Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for EDSA (100) in the null industry. This means that ORMP’s stock grew significantly faster than EDSA’s over the last 12 months.

ORMP's Price Growth Rating (43) in the Pharmaceuticals Other industry is in the same range as EDSA (65) in the null industry. This means that ORMP’s stock grew similarly to EDSA’s over the last 12 months.

EDSA's P/E Growth Rating (9) in the null industry is significantly better than the same rating for ORMP (92) in the Pharmaceuticals Other industry. This means that EDSA’s stock grew significantly faster than ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDSAORMP
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
72%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (EDSA: $2.85 vs. ORMP: $4.14)
Brand notoriety: EDSA and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDSA: 50% vs. ORMP: 49%
Market capitalization -- EDSA: $27.48M vs. ORMP: $172.21M
EDSA [@Biotechnology] is valued at $27.48M. ORMP’s [@Biotechnology] market capitalization is $172.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDSA’s FA Score shows that 1 FA rating(s) are green while ORMP’s FA Score has 1 green FA rating(s).

  • EDSA’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 1 green, 4 red.
According to our system of comparison, ORMP is a better buy in the long-term than EDSA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDSA’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).

  • EDSA’s TA Score: 4 bullish, 5 bearish.
  • ORMP’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both EDSA and ORMP are a bad buy in the short-term.

Price Growth

EDSA (@Biotechnology) experienced а +7.55% price change this week, while ORMP (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.

Reported Earning Dates

EDSA is expected to report earnings on Dec 11, 2026.

ORMP is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-1.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDSA
Daily Signal:
Gain/Loss:
ORMP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

EDSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDSA has been loosely correlated with MBRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if EDSA jumps, then MBRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDSA
1D Price
Change %
EDSA100%
+1.06%
MBRX - EDSA
38%
Loosely correlated
+1.94%
DOMH - EDSA
37%
Loosely correlated
+2.94%
TAOX - EDSA
33%
Poorly correlated
+4.88%
ORMP - EDSA
32%
Poorly correlated
-0.24%
RNAZ - EDSA
31%
Poorly correlated
N/A
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with DRTS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then DRTS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-0.24%
DRTS - ORMP
53%
Loosely correlated
+2.98%
INO - ORMP
44%
Loosely correlated
-21.26%
MBIO - ORMP
44%
Loosely correlated
-0.13%
CGEM - ORMP
42%
Loosely correlated
+0.40%
CGEN - ORMP
41%
Loosely correlated
-0.93%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CEFD17.340.14
+0.82%
ETRACS Monthly Pay 1.5X Leveraged Closed-End Fund Index ETN (CEFD)
KNO63.700.42
+0.66%
AXS Knowledge Leaders ETF (KNO)
XYLD41.540.14
+0.34%
Global X S&P 500 Covered Call ETF (XYLD)
HYEM19.330.02
+0.13%
VanEck Emerging Markets High Yield Bond ETF (HYEM)
RWM14.51-0.03
-0.21%
ProShares Short Russell2000 (RWM)